Cargando…
Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis
OBJECTIVE: To compare the clinical efficacy and safety of nimotuzumab combined with chemotherapy versus chemotherapy alone as first-line treatment for advanced colorectal cancer (ACRC). METHOD: We retrospectively enrolled patients with ACRC treated with nimotuzumab plus chemotherapy (n = 40) or chem...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113702/ https://www.ncbi.nlm.nih.gov/pubmed/31948326 http://dx.doi.org/10.1177/0300060519895858 |
_version_ | 1783513729103560704 |
---|---|
author | Bai, Sai-xi Zhang, Ruo-rong Chen, Wang-hua Dong, Hong-min Wang, Gang Li, Xiao-kai Wang, Wenling |
author_facet | Bai, Sai-xi Zhang, Ruo-rong Chen, Wang-hua Dong, Hong-min Wang, Gang Li, Xiao-kai Wang, Wenling |
author_sort | Bai, Sai-xi |
collection | PubMed |
description | OBJECTIVE: To compare the clinical efficacy and safety of nimotuzumab combined with chemotherapy versus chemotherapy alone as first-line treatment for advanced colorectal cancer (ACRC). METHOD: We retrospectively enrolled patients with ACRC treated with nimotuzumab plus chemotherapy (n = 40) or chemotherapy alone (n = 44). Responses were evaluated according to the Response Evaluation Criteria in Solid Tumors and adverse events according to the Common Terminology Criteria for Adverse Events 3.0. RESULTS: The objective overall response rate and disease control rate were higher in the combined-treatment group (55.0% vs 36.4% and 85.0% vs 75.0%, respectively), but the differences were not significant. There was no significant difference in median progression-free survival or median survival time between the combined-treatment and chemotherapy-alone groups (9.89 vs 7.86 months and 22.32 vs 18.10 months, respectively). There was no significant difference in adverse events between the two groups. CONCLUSION: Nimotuzumab combined with chemotherapy had similar efficacy and safety to chemotherapy alone in patients with ACRC. The efficacy and safety of the combined treatment should be further studied in a randomized multicenter trial with a larger number of patients with ACRC. |
format | Online Article Text |
id | pubmed-7113702 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-71137022020-04-09 Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis Bai, Sai-xi Zhang, Ruo-rong Chen, Wang-hua Dong, Hong-min Wang, Gang Li, Xiao-kai Wang, Wenling J Int Med Res Retrospective Study OBJECTIVE: To compare the clinical efficacy and safety of nimotuzumab combined with chemotherapy versus chemotherapy alone as first-line treatment for advanced colorectal cancer (ACRC). METHOD: We retrospectively enrolled patients with ACRC treated with nimotuzumab plus chemotherapy (n = 40) or chemotherapy alone (n = 44). Responses were evaluated according to the Response Evaluation Criteria in Solid Tumors and adverse events according to the Common Terminology Criteria for Adverse Events 3.0. RESULTS: The objective overall response rate and disease control rate were higher in the combined-treatment group (55.0% vs 36.4% and 85.0% vs 75.0%, respectively), but the differences were not significant. There was no significant difference in median progression-free survival or median survival time between the combined-treatment and chemotherapy-alone groups (9.89 vs 7.86 months and 22.32 vs 18.10 months, respectively). There was no significant difference in adverse events between the two groups. CONCLUSION: Nimotuzumab combined with chemotherapy had similar efficacy and safety to chemotherapy alone in patients with ACRC. The efficacy and safety of the combined treatment should be further studied in a randomized multicenter trial with a larger number of patients with ACRC. SAGE Publications 2020-01-17 /pmc/articles/PMC7113702/ /pubmed/31948326 http://dx.doi.org/10.1177/0300060519895858 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Retrospective Study Bai, Sai-xi Zhang, Ruo-rong Chen, Wang-hua Dong, Hong-min Wang, Gang Li, Xiao-kai Wang, Wenling Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis |
title | Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis |
title_full | Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis |
title_fullStr | Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis |
title_full_unstemmed | Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis |
title_short | Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis |
title_sort | clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113702/ https://www.ncbi.nlm.nih.gov/pubmed/31948326 http://dx.doi.org/10.1177/0300060519895858 |
work_keys_str_mv | AT baisaixi clinicalefficacyandsafetyofnimotuzumabpluschemotherapyinpatientswithadvancedcolorectalcanceraretrospectiveanalysis AT zhangruorong clinicalefficacyandsafetyofnimotuzumabpluschemotherapyinpatientswithadvancedcolorectalcanceraretrospectiveanalysis AT chenwanghua clinicalefficacyandsafetyofnimotuzumabpluschemotherapyinpatientswithadvancedcolorectalcanceraretrospectiveanalysis AT donghongmin clinicalefficacyandsafetyofnimotuzumabpluschemotherapyinpatientswithadvancedcolorectalcanceraretrospectiveanalysis AT wanggang clinicalefficacyandsafetyofnimotuzumabpluschemotherapyinpatientswithadvancedcolorectalcanceraretrospectiveanalysis AT lixiaokai clinicalefficacyandsafetyofnimotuzumabpluschemotherapyinpatientswithadvancedcolorectalcanceraretrospectiveanalysis AT wangwenling clinicalefficacyandsafetyofnimotuzumabpluschemotherapyinpatientswithadvancedcolorectalcanceraretrospectiveanalysis |